Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Biovitrum claims 5-HT6 modulators for obesity and other disorders

Feb. 6, 2004

New liver-selective GR antagonists prepared and tested at Abbott

Feb. 6, 2004

Three series of hypolipidemic agents presented by Aventis Pharma

Feb. 6, 2004

Kissei obtains marketing approval of Glufast in Japan

Feb. 5, 2004

OrthoLogic continued progress with Chrysalin product platform during the past year

Feb. 5, 2004

Unacceptable safety profile found for HRT in breast cancer survivors

Feb. 5, 2004

Treatment completed in phase II FM-VP4 trial

Feb. 5, 2004

Positive preclinical results for GLP1-I.N.T

Feb. 5, 2004

Bayer to distribute Testim in Canada

Feb. 5, 2004

New 5-HT2C agonists for obesity and other disorders covered by Biovitrum patent

Feb. 5, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...